Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ventyx Biosciences, Inc.

2.46
+0.21009.33%
Post-market: 2.40-0.0600-2.44%19:37 EDT
Volume:3.52M
Turnover:8.33M
Market Cap:175.06M
PE:-1.40
High:2.47
Open:2.23
Low:2.23
Close:2.25
Loading ...

Ventyx Biosciences Inc expected to post a loss of 54 cents a share - Earnings Preview

Reuters
·
22 Feb

Ventyx Biosciences Announces Presentation of Data From the Phase 2 Trial of Allosteric Tyk2 Inhibitor Vtx958 in Crohn’s Disease at Ecco 2025

THOMSON REUTERS
·
18 Feb

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025

GlobeNewswire
·
18 Feb

Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) high institutional ownership speaks for itself as stock continues to impress, up 10% over last week

Simply Wall St.
·
23 Jan

Ventyx Biosciences (VTYX) Gets a Hold from H.C. Wainwright

TIPRANKS
·
15 Jan

Ventyx’s Phase 2 programs ‘high risk/high reward,’ says H.C. Wainwright

TIPRANKS
·
15 Jan

Ventyx Biosciences Unveils 2025 Pipeline and Clinical Updates

TIPRANKS
·
14 Jan

Ventyx Biosciences highlights its 2025 pipeline strategy

TIPRANKS
·
14 Jan

Ventyx Biosciences: Phase 2 Trial of Vtx2735 in Participants With Recurrent Pericarditis Expected to Initiate in Jan

THOMSON REUTERS
·
14 Jan

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on Its Nlrp3 Inhibitor Portfolio

THOMSON REUTERS
·
14 Jan

Ventyx Biosciences: Topline Data From Ongoing Phase 2 Biomarker Trial of Vtx3232 in Participants With Early Parkinson's Disease Expected in H1 2025

THOMSON REUTERS
·
14 Jan

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

GlobeNewswire
·
14 Jan

We're Keeping An Eye On Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

Simply Wall St.
·
10 Jan

Ventyx Biosciences Insiders Land Bargain With Gains Of US$180k

Simply Wall St.
·
14 Dec 2024